Oswiecimska J, Brus R, Szkilnik R, Nowak P, Kostrzewa R M
Department of Pharmacology, Silesian Medical University, H. Jordana 38, 41-808, Zabrze, Poland.
Pharmacol Biochem Behav. 2000 Sep;67(1):11-5. doi: 10.1016/s0091-3057(00)00296-3.
Repeated treatment in ontogeny with the dopamine (DA) D(2)/D(3) receptor agonist quinpirole is associated with enhanced quinpirole-induced yawning and other behaviors such as vacuous chewing, vertical jumping, and antinociception. To determine if the reputedly DA D(3) agonist (+/-)-2-(dipropylamino)-7-hydroxy-1,2,3, 4-tetrahydronaphthalene (7-OH-DPAT) would prime for yawning in a manner analogous to that for quinpirole, rats were treated for the first 11 days after birth with an equimolar dose of either quinpirole or 7-OH-DPAT (195.4 nmol/kg/day) and tested for agonist-induced yawning in adulthood. While enhanced quinpirole-induced and 7-OH-DPAT-induced yawning was observed in quinpirole-primed rats, acute treatments with quinpirole and 7-OH-DPAT did not produce an enhanced yawing response in 7-OH-DPAT-"primed" rats. Our findings indicate that 7-OH-DPAT, unlike quinpirole, does not prime for quinpirole- or 7-OH-DPAT-induced yawning in rats.
在个体发育过程中，用多巴胺（DA）D(2)/D(3)受体激动剂喹吡罗反复治疗会导致喹吡罗诱导的打哈欠以及其他行为增强，如空嚼、垂直跳跃和抗伤害感受。为了确定所谓的DA D(3)激动剂（±）-2-（二丙基氨基）-7-羟基-1,2,3,4-四氢萘（7-OH-DPAT）是否会以类似于喹吡罗的方式引发打哈欠，在出生后的前11天，用等摩尔剂量的喹吡罗或7-OH-DPAT（195.4 nmol/kg/天）对大鼠进行治疗，并在成年后测试激动剂诱导的打哈欠情况。虽然在喹吡罗预处理的大鼠中观察到喹吡罗诱导的和7-OH-DPAT诱导的打哈欠增强，但用喹吡罗和7-OH-DPAT进行急性治疗在7-OH-DPAT“预处理”的大鼠中并未产生增强的打哈欠反应。我们的研究结果表明，与喹吡罗不同，7-OH-DPAT不会引发大鼠对喹吡罗或7-OH-DPAT诱导的打哈欠。
